Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Armand, Philippe, Zinzani, Pier Luigi, Lee, Hun Ju, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Herrera, Alex F., Lin, Jianxin, Kim, Eunhee, Chakraborty, Samhita, Marinello, Patricia, Moskowitz, Craig H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624931/
https://www.ncbi.nlm.nih.gov/pubmed/37319435
http://dx.doi.org/10.1182/blood.2022019386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624931/
https://www.ncbi.nlm.nih.gov/pubmed/37319435
http://dx.doi.org/10.1182/blood.2022019386

Ejemplares similares